Unknown

Dataset Information

0

Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model


ABSTRACT: Ceftolozane/tazobactam (C/T) has emerged as a potential agent for the treatment of extensively drug-resistant (XDR) Pseudomonas aeruginosa infections. As it is a time-dependent antimicrobial, prolonged infusion may help achieve pharmacokinetic/pharmacodynamic (PK/PD) targets. To compare alternative steady-state concentrations (Css) of C/T in continuous infusion (CI) against three XDR P. aeruginosa ST175 isolates with C/T minimum inhibitory concentration (MIC) values of 2 to 16 mg/L in a hollow-fiber infection model (HFIM). Duplicate 10-day HFIM assays were performed to evaluate Css of C/T in CI: one compared 20 and 45 mg/L against the C/T-susceptible isolate while the other compared 45 and 80 mg/L against the two C/T-non-susceptible isolates. C/T resistance emerged when C/T-susceptible isolate was treated with C/T in CI at a Css of 20 mg/L; which showed a deletion in the gene encoding AmpC β-lactamase. The higher dosing regimen (80 mg/L) showed a slight advantage in effectiveness. The higher dosing regimen has the greatest bactericidal effect, regardless of C/T MIC. Exposure to the suboptimal Css of 20 mg/L led to the emergence of C/T resistance in the susceptible isolate. Antimicrobial regimens should be optimized through C/T levels monitoring and dose adjustments to improve clinical management.

SUBMITTER: Montero M 

PROVIDER: S-EPMC8589991 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9241897 | biostudies-literature
| S-EPMC7672432 | biostudies-literature
| S-EPMC3754319 | biostudies-literature
| S-EPMC8275882 | biostudies-literature
| S-EPMC8527844 | biostudies-literature
| PRJEB20248 | ENA
| S-EPMC10408163 | biostudies-literature
| S-EPMC7885320 | biostudies-literature
| S-EPMC4914619 | biostudies-literature
| S-EPMC5328537 | biostudies-literature